Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:AUPH NASDAQ:CALT NASDAQ:CVAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.16+4.4%$14.46$7.08▼$17.49$300.67M0.8481,295 shs88,516 shsAUPHAurinia Pharmaceuticals$10.49+13.5%$8.35$5.20▼$10.67$1.25B1.231.95 million shs7.74 million shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACVACCureVac$5.41+0.4%$5.17$2.37▼$5.72$1.21B2.53838,251 shs516,327 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+4.41%-1.49%-8.95%+38.96%+11.14%AUPHAurinia Pharmaceuticals+13.53%+17.47%+40.05%+27.77%+78.40%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+4.03%CVACCureVac+0.37%-0.92%+0.19%+51.97%+43.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.5783 of 5 stars0.55.00.00.01.70.00.6AUPHAurinia Pharmaceuticals2.3275 of 5 stars2.51.00.00.02.00.83.1CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ACVACCureVac4.4413 of 5 stars4.13.00.04.92.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.00Sell$12.00-20.84% DownsideAUPHAurinia Pharmaceuticals 3.00Buy$12.0014.39% UpsideCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/ACVACCureVac 2.20Hold$6.8326.31% UpsideCurrent Analyst Ratings BreakdownLatest AMRN, CVAC, AUPH, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025AUPHAurinia PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $9.007/30/2025AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.006/26/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.506/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSell ➝ Sell$7.00 ➝ $12.006/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/12/2025CVACCureVacCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform6/12/2025CVACCureVacCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/28/2025CVACCureVacJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$10.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.37N/AN/A$22.45 per share0.68AUPHAurinia Pharmaceuticals$235.13M6.03$0.35 per share29.98$2.68 per share3.91CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74CVACCureVac$579.18M2.10$0.88 per share6.17$3.36 per share1.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%N/AAUPHAurinia Pharmaceuticals$5.75M$0.2824.4018.73N/A23.31%19.57%13.60%N/ACALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ACVACCureVac$175.50M$0.925.88N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)Latest AMRN, CVAC, AUPH, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CVACCureVac-$0.15N/AN/AN/A$4.27 millionN/A7/31/2025Q2 2025AUPHAurinia Pharmaceuticals$0.17$0.16-$0.01$0.16$64.27 million$70.01 million7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 million5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.262.55AUPHAurinia Pharmaceuticals0.165.935.26CALTCalliditas Therapeutics AB (publ)9.442.692.59CVACCureVac0.057.657.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%AUPHAurinia Pharmaceuticals36.83%CALTCalliditas Therapeutics AB (publ)2.83%CVACCureVac17.26%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%AUPHAurinia Pharmaceuticals12.20%CALTCalliditas Therapeutics AB (publ)2.20%CVACCureVac2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.71 million20.02 millionOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableCVACCureVac880224.34 million219.52 millionOptionableAMRN, CVAC, AUPH, and CALT HeadlinesRecent News About These CompaniesCVAC - CureVac NV Ordinary Shares Key Metrics - MorningstarJuly 9, 2025 | morningstar.comMCureVac N.V. (CVAC) Has Gained Over 16% In One Month. Here Is WhyJuly 9, 2025 | insidermonkey.comCureVac (NASDAQ:CVAC) Trading Down 0.1% - What's Next?July 5, 2025 | marketbeat.comUBS Downgrades CureVac N.V. (CVAC)June 27, 2025 | msn.comCureVac Announces Voting Results of General MeetingJune 24, 2025 | accessnewswire.comACureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTechJune 20, 2025 | zacks.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)June 20, 2025 | globenewswire.comBioNTech SE Announces Acquisition of CureVac N.V.June 17, 2025 | tipranks.comM&A News: BioNTech Snaps Up CureVac in $1.25B Deal to Supercharge Cancer PipelineJune 14, 2025 | theglobeandmail.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of ShareholdersJune 13, 2025 | globenewswire.comCureVac stock soars about 30% after BioNTech agrees to acquire coJune 13, 2025 | finance.yahoo.comBioNTech Announces Strategic Acquisition of CureVacJune 12, 2025 | tipranks.comBioNTech to Acquire CureVac in Strategic mRNA ExpansionJune 12, 2025 | tipranks.comBioNTech (BNTX) to Acquire CureVac for $1.25 Billion | BNTX Stock NewsJune 12, 2025 | gurufocus.comBioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock DealJune 12, 2025 | benzinga.comTop Stock Movers Now: Oracle, Boeing, CureVac, and MoreJune 12, 2025 | investopedia.comM&A News: BioNTech (BNTX) Acquires CureVac in $1.25 Billion DealJune 12, 2025 | tipranks.comCureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On ThursdayJune 12, 2025 | benzinga.comCureVac Stock Soars on BioNTech BuyoutJune 12, 2025 | schaeffersresearch.comBioNTech boosts cancer mRNA pipeline with CureVac acquisitionJune 12, 2025 | proactiveinvestors.comCVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to ShareholdersJune 12, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMRN, CVAC, AUPH, and CALT Company DescriptionsAmarin NASDAQ:AMRN$15.16 +0.64 (+4.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.08 -0.09 (-0.56%) As of 08/1/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Aurinia Pharmaceuticals NASDAQ:AUPH$10.49 +1.25 (+13.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.42 -0.08 (-0.71%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 08/1/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.CureVac NASDAQ:CVAC$5.41 +0.02 (+0.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.40 -0.02 (-0.28%) As of 08/1/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.